Liver transplant with delayed removal of the original liver for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new way to treat liver cancer by first transplanting part of a donor liver while keeping most of the original liver, then removing the remaining cancer later. It may help patients with liver cancer who need a transplant but have limited options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 68 years old.
- You have been approved for a liver transplant for liver cancer by a team of specialists.
- Your body mass index (BMI) is less than 30.
- Your liver function score (MELD) is 15 or lower, and you do not qualify for priority listing.
- Imaging scans (PET CT-choline and PET CT-FDG) show no cancer spread outside the liver.
- You have not had major abdominal surgery, a liver transplant, or certain other treatments like radioembolization, radiation, or immunotherapy.
- You do not have active hepatitis B, C, HIV, or severe heart, lung, or kidney disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of two immunotherapy drugs before a liver transplant can help people with advanced liver cancer (beyond standard size limits) receive a transplant successfully. The treatment aims to shrink the tumor and improve outcomes.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This study looks at whether combining different liver-directed treatments with newer cancer drugs can help people with liver cancer who are waiting for a liver transplant. It aims to see if these treatments are safe and helpful for a wider group of patients.
This trial tests if a liver transplant can help people with a certain type of bile duct cancer (intrahepatic cholangiocarcinoma) that cannot be removed by surgery. Before the transplant, you would receive radiation therapy (SIRT) and chemotherapy to shrink the tumor.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.